Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 29, 2015

Primary Completion Date

June 15, 2018

Study Completion Date

December 24, 2018

Conditions
Multiple Sclerosis (MS)
Interventions
BIOLOGICAL

Mesenchymal stem cells

A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.

Trial Locations (1)

91120

Hadassah Medical Organization, Jerusalem

All Listed Sponsors
lead

Dimitrios Karussis

OTHER

NCT02166021 - Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis | Biotech Hunter | Biotech Hunter